Hepatocellular carcinoma

Lancet

Volumn 362, Issue 9399, 2003, Pages 1907-1917

  Llovet, Josep M ^a   Burroughs, Andrew ^b   Bruix, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; INTERFERON; IODINATED POPPYSEED OIL; IODINE 131; MEGESTROL; MITOMYCIN; OCTREOTIDE; TAMOXIFEN;

ARTIFICIAL EMBOLISM; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; ECHOGRAPHY; GEOGRAPHY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; META ANALYSIS; ORGAN DONOR; PALLIATIVE THERAPY; PATHOLOGY; PATIENT MONITORING; PATIENT SELECTION; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; TUMOR VOLUME;

EID: 0141491273     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14964-1     Document Type: Conference Paper

References (129)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 94:2001;153-156.
2. Deuffic S., Poynard T., Buffat L., Valleron A.J. Trends in primary liver cancer. Lancet. 351:1998;214-215.
3. El Serag H.B., Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 340:1999;745-750.
4. Tanaka Y., Hanada K., Mizokami M., et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci. 99:2002;15584-15589.
5. Fattovich G., Giustina G., Degos F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 112:1997;463-472.
6. Bosch X., Ribes J., Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis. 19:1999;271-285.
7. Colombo M. Risk groups and preventive strategies. Berr F., Bruix J., Hauss J., Wands J., Wittekind Ch. Malignant liver tumors: basic concepts and clinical management. 2003;67-74 Kluwer Academic Publishers BV and Falk Foundation, Dordrecht.
8. Liaw Y.F., Tai D.I., Chu C.M., et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis: a prospective study. Gastroenterology. 90:1986;263-267.
9. Sun Z., Lu P., Gail M.H. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable aflatoxin metabolite M1. Hepatology. 30:1999;379-383.
10. Bruno S., Silini E., Crosignani A., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 25:1997;754-758.
11. Bruix J., Barrera J.M., Calvet X., et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 2:1989;1004-1006.
12. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 325:1991;675-680.
13. Tsukuma H., Hiyama T., Tanaka S., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 328:1993;1797-1801.
14. Niederau C., Fischer R., Sonnenberg A., Stremmel W., Trampisch H.J., Strohmeyer G. Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary hemochromatosis. N Engl J Med. 313:1985;1256-1262.
15. Buendia M.A. Genetics of hepatocellular carcinoma. Semin Cancer Biol. 10:2000;185-200.
16. Thorgeirsson S., Grisham J. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:2002;339-346.
17. Zhou X.D., Tang Z.Y., Yang B.H., et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 91:2001;1479-1486.
18. Margolis H.S., Alter M.J., Hadler S.C. Viral hepatitis. Evans A.S., Kaslow R.A. Viral infections in humans. 4th edn :1997;363-418 Plenum Medical Book Co, New York.
19. Bréchot C., Thiers V., Kremsdorf D., Nalpas B., Pol S., Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology. 34:2001;194-203.
20. Beasley R.P., Hwang L.Y., Lin C.C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 2:1981;1129-1133.
21. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 21:1995;77-82.
22. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 336:1997;1855-1859.
23. Chang M.H., Shau W.Y., Chen C.J., et al. The Taiwan Childhood Hepatoma Study Group: hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. JAMA. 284:2000;3040-3042.
24. Hepatitis C: global prevalence. Wkly Epidemiol Rec. 72:1997;341-344.
25. Forns X., Bukh J., Purcell R.H. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 37:2002;684-695.
26. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 358:2001;958-965.
27. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol ; 35. 35:2001;421-430.
28. Collier J., Sherman M. Screening for hepatocellular carcinoma. Hepatology. 27:1998;273-278.
29. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut. 48:2001;251-259.
30. Sarasin F.P., Giostra E., Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in Western patients with Child-Pugh class A cirrhosis. Am J Med. 101:1996;422-434.
31. Mion F., Grozel L., Boillot O., Paliard P., Berger F. Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas. Gastroenterology. 111:1996;1587-1592.
32. Terminology of nodular hepatocellular lesions. Hepatology. 17:1995;27-35.
33. Takayama T., Makuuchi M., Hirohashi S., et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet. 336:1990;1150-1153.
34. Durand F., Regimbeau J.M., Belghiti J., et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol. 35:2001;254-258.
35. Kim C.K., Lim J.H., Lee W.J. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med. 20:2001;99-104.
36. Lencioni R., Cioni D., Bartolozzi C. Tissue harmonic and contrast-specific imaging: back to gray scale ultrasound. Eur Radiol. 12:2002;151-165.
37. Choi D., Kim S.H., Lim J.H., et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr. 25:2001;777-785.
38. Burrel M., Llovet J.M., Ayuso C., et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantion: an explant correlation. Hepatology. 38:2003;1034-1042.
39. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 56:1985;918-928.
40. Bruix J., Llovet J.M. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 35:2002;519-524.
41. Barbara L., Benzi G., Gaiani S., et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 16:1992;132-137.
42. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:1996;693-699.
43. Llovet J.M., Fuster J., Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 39:1999;1434-1440.
44. Arii S., Yamaoka Y., Futagawa S., et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. Hepatology. 32:2000;1224-1229.
45. Bruix J., Castells A., Bosch J., et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 111:1996;1018-1022.
46. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 74:1994;2272-2280.
47. Bismuth H., Chiche L., Adam R., Castaing D., Diamond T., Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg. 218:1993;145-151.
48. Livraghi T., Bolondi L., Buscarini L., et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol. 22:1995;522-526.
49. Ebara M., Ohto M., Shinagawa T., et al. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis: a study in 22 patients. Gastroenterology. 90:1986;289-298.
50. Tang Z.Y., Yu Y.Q., Zhou X.D., Yang B.H., Ma Z.C., Lin Z.Y. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl. 3:1993;55-58.
51. Takayama T., Makuuchi S., Hirohashi S., et al. Early hepatocellular carcinoma as an entity with high rate of surgical cure. Hepatology. 28:1998;1241-1246.
52. Kojiro M. The evolution of pathologic features of hepatocellular carcinoma. Tabor E. Viruses and liver cancer: perspectives in medical virology. 2002;113-122 Elsevier Science, Amsterdam.
53. Sakamoto M., Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol. 28:1998;604-608.
54. Llovet J.M., Bru C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 19:1999;329-338.
55. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 37:2003;429-442.
56. Llovet J.M., Bustamante J., Castells A., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 29:1999;62-67.
57. Villa E., Moles A., Ferretti I., et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 32:2000;233-238.
58. Chevret S., Trinchet J.C., Mathieu D., Rached A.A., Beaugrand M., Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol. 31:1999;133-141.
59. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 31:2000;840-845.
60. Leung T.W., Tang A.M., Zee B., et al. Construction of the Chinese University prognostic index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the cancer of the liver Italian program staging system: a study based on 926 patients. Cancer. 94:2002;1760-1769.
61. Llovet J.M., Moitinho E., Sala M., et al. Prevalence and prognostic value of hepatocellular carcinoma in cirrhotic patients with spontaneous bacterial peritonitis. J Hepatol. 33:2000;423-429.
62. Vauthey J., Lauwers G., Esnaola N., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol. 20:2002;1527-1536.
63. Llovet J.M., Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol. 38:(suppl 1):2003;S136-149.
64. Befeler A.S., Di Bisceglie A.M. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 122:2002;1609-1619.
65. Sato S., Shiratori Y., Imamura M., et al. Power Doppler signals after percutaneous ethanol injection therapy for hepatocellular carcinoma predict local recurrence of tumors: a prospective study using 199 consecutive patients. J Hepatol. 35:2001;225-234.
66. Takayama T., Makuuchi M. Ablation of hepatocellular carcinoma. Jpn J Clin Oncol. 31:2001;297-298.
67. Fong Y., Sun R.L., Jarnagin W., Blumgart L.H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 229:1999;790-799.
68. Takayama T., Sekine T., Makuuchi M., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 356:2000;802-807.
69. Wayne J.D., Lauwers G.Y., Ikai I., et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 235:2002;722-731.
70. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 214:1991;221-228.
71. Bismuth H., Majno P.E., Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 19:1999;311-322.
72. Jonas S., Bechstein W.O., Steinmuller T., et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 33:2001;1080-1086.
73. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology. 33:2001;1394-1403.
74. Livraghi T., Giorgio A., Marin G., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 197:1995;101-108.
75. Lencioni R., Pinto F., Armillotta N., et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur Radiol. 7:1997;514-519.
76. Rossi S., Di Stasi M., Buscarini E., et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am J Roentgenol. 167:1996;759-768.
77. Buscarini L., Buscarini E., Di Stasi M. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol. 11:2001;914-921.
78. Bismuth H., Majno P. Hepatobiliary surgery. J Hepatol. 32:2000;208-224.
79. Makuuchi M., Kosuge T., Takayama T., et al. Surgery for small liver cancers. Semin Surg Oncol. 9:1993;298-304.
80. Nagasue N., Uchida M., Makino Y., et al. Incidence and factors associated with intrahepatic recurrence following resection of hepatocellular carcinoma. Gastroenterology. 105:1993;488-494.
81. Schwartz J.D., Schwartz M., Mandeli J., Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 3:2002;593-603.
82. Lau W.Y., Leung T.W., Ho S.K., et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 353:1999;797-801.
83. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med. 334:1996;1561-1567.
84. Ringe B., Pichlmayr R., Wittekind C., Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 15:1991;270-285.
85. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 8:2002;873-883.
86. United Network for Organ Sharing. Annual report 2002. http://www.unos.org/data/annualReport.asp (accessed Sept 30, 2003).
87. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 33:2001;464-470.
88. Freeman R., Wiesner R., Harper A., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 8:2002;851-858.
89. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 124:2003;91-96.
90. Nair S., Verma S., Thuluvath P. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology. 35:2002;1179-1185.
91. Majno P.E., Adam R., Bismuth H., et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 226:1997;688-701.
92. Llovet J.M., Mas X., Aponte J., et al. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation. Gut. 50:2002;123-128.
93. Trotter J., Wachs M., Everson G., Kam I. Adult-to-adult transplantation of the right hepatic lobe from living donor. N Engl J Med. 14:2002;1074-1082.
94. Gondolesi G, Roayale S, Muñoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma. Ann Surg (in press).
95. Sarasin F., Majno P., Llovet J.M., Mentha J., Bruix J., Hadengue A. Liver donor liver transplantation for early hepatocellular carcinoma: a cost-effectiveness perspective. Hepatology. 33:2001;1073-1079.
96. Cronin D., Millis M., Siegler M. Transplantation of liver grafts from living donors into adults: too much, too soon. N Engl J Med. 344:2001;1633-1637.
97. Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis. 19:1999;323-328.
98. Livraghi T., Goldberg S.N., Lazzaroni S., Meloni F., Solbiati L., Gazelle G.S. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 210:1999;655-661.
99. Lencioni R., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 228:2003;235-240.
100. Mulier S., Mulier P., Ni Y., et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 89:2002;1206-1222.
101. Llovet J.M., Vilana R., Brú C., et al. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. Hepatology. 33:2001;1124-1129.
102. Kawai S., Okamura J., Ogawa M., et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). Cancer Chemother Pharmacol. 31:1992;S1-6.
103. Kawai S., Tani M., Okamura J., et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison of L-TAE with farmorubicin and L-TAE with adriamycin (second cooperative study). Cancer Chemother Pharmacol. 33:1994;S97-102.
104. Lin D.Y., Liaw Y.F., Lee T.Y., Lai C.M. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Gastroenterology. 94:1988;453-456.
105. Pelletier G., Roche A., Ink O., et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 11:1990;181-184.
106. Group d'Etude et de Traitment du Carcinome Hépatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-1261.
107. Bruix J., Llovet J.M., Castells A., et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 127:1998;1578-1583.
108. Pelletier G., Ducreux M., Gay F., et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol. 29:1998;129-134.
109. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 35:2002;1164-1171.
110. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 359:2002;1734-1739.
111. Kawai S., Tani M., Okamura J., et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). Semin Oncol. 24:1997;S6.
112. Raoul J.L., Guyader D., Bretagne J.F., et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 26:1997;1156-1161.
113. Elba S., Giannuzzi V., Misciagna G., Manghisi O.G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol. 26:1994;66-68.
114. Martinez-Cerezo F.J., Tomas A., Donoso L., et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 20:1994;702-706.
115. Castells A., Bruix J., Bru C., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology. 109:1995;917-922.
116. Manesis E.K., Giannoulis G., Zoumboulis P., Vafiadou I., Hadziyannis S.J. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology. 21:1995;1535-1542.
117. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet. 352:1998;17-20.
118. Riestra S., Rodriguez M., Delgado M., et al. Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma. J Clin Gastroenterol. 26:1998;200-203.
119. Liu C.L., Fan S.T., Ng I.O., Lo C.M., Poon R.T., Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 95:2000;218-222.
120. Chow P.K., Tai B.C., Tan C.K., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 36:2002;1221-1226.
121. Villa E., Ferretti I., Grottola A., et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 84:2001;881-885.
122. Grimaldi C., Bleiberg H., Gay F., et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 16:1998;411-417.
123. Lai C.L., Lau J.Y., Wu P.C., et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 17:1993;389-394.
124. Llovet J.M., Sala M., Castells L., et al. Randomized controlled trial of Interferon treatment for advanced hepatocellular carcinoma. Hepatology. 31:2000;54-58.
125. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J., Manousos O.N. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 42:1998;442-447.
126. Yuen M., Poon R., Lai Ch, et al. A randomized placebo-controlled study of long-acting octeotride for the treatment of advanced hepatocellular carcinoma. Hepatology. 36:2002;687-691.
127. Boix L., Bruix J., Castells A., et al. Sex hormone receptors in hepatocellular carcinoma: is there a rationale for hormonal treatment? J Hepatol. 17:1993;187-191.
128. Mor E., Kaspa R.T., Sheiner P., Schwartz M. Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation. Ann Intern Med. 129:1998;643-653.
129. Poon R.T., Fan S.T., Tsang F.H., Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 235:2002;466-486.